Vertex Pharmaceuticals (VRTX) Retained Earnings (2009 - 2026)

Vertex Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at $14.6 billion for Q1 2026.

• In Q1 2026, Retained Earnings rose 21326.43% year-over-year to $14.6 billion; the TTM figure through Mar 2026 stood at $14.6 billion (up 21326.43% YoY), while the FY2025 annual figure was $13.6 billion, up 10510.33% from the prior year.
• Retained Earnings for Q1 2026 stood at $14.6 billion, up from $13.6 billion in the prior quarter.
• The five-year high for Retained Earnings was $14.6 billion in Q1 2026, with the low at -$64.5 million in Q3 2025.
• The 5-year median for Retained Earnings is $68.1 million (2025), against an average of $3.5 billion.
• The sharpest annual moves came in 2023 and 2024: Retained Earnings slumped 1887.5% in 2023, then jumped 289893.33% in 2024.
• Vertex Pharmaceuticals' Retained Earnings stood at $800000.0 in 2022, then plunged by 1887.5% to -$14.3 million in 2023, then soared by 993.71% to $127.8 million in 2024, then soared by 10510.33% to $13.6 billion in 2025, then rose by 7.61% to $14.6 billion in 2026.
• Business Quant data shows VRTX's Retained Earnings at $14.6 billion in Q1 2026, $13.6 billion in Q4 2025, and -$64.5 million in Q3 2025.